Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- methylnaltrexone
- pitolisant
Interactions between your drugs
methylnaltrexone pitolisant
Applies to: methylnaltrexone, pitolisant
MONITOR: Coadministration with pitolisant may increase plasma concentrations of substrates of the hepatic and intestinal uptake transporter, organic cation transporter 1 (OCT1). Pitolisant has demonstrated inhibitory potential towards OCT1 in vitro. The clinical significance of this effect has not been established.
MANAGEMENT: Caution is recommended when pitolisant is administered with OCT1 substrates.
References (1)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
Drug and food interactions
methylnaltrexone food
Applies to: methylnaltrexone
ADJUST DOSING INTERVAL: Food may reduce the rate and extent of absorption of methylnaltrexone following oral administration. When a single 450 mg oral dose of methylnaltrexone was administered with a high-fat breakfast (approximately 800 to 1000 calories; 60% from fat, 25% from carbohydrate, and 15% from protein) in healthy study subjects, methylnaltrexone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 60% and 43%, respectively, while time to reach Cmax delayed by 2 hours.
MANAGEMENT: Oral methylnaltrexone should be taken with water on an empty stomach at least 30 minutes before the first meal of the day.
References (1)
- (2008) "Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
MiraLAX
MiraLAX (polyethylene glycol) is used as a laxative to treat occasional constipation or irregular ...
Colace
Colace makes bowel movements softer and is used to treat or prevent constipation. Includes Colace ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Linzess
Linzess (linaclotide) is used to treat chronic idiopathic constipation, irritable bowel syndrome ...
Dulcolax
Dulcolax (bisacodyl) is a laxative used to treat constipation. Includes Dulcolax side effects ...
Metamucil
Metamucil is used for constipation, dietary fiber supplementation, irritable bowel syndrome
Amitiza
Amitiza (lubiprostone) is used to treat chronic constipation and irritable bowel syndrome with ...
GoLYTELY
GoLYTELY is used for bowel preparation, constipation, chronic, gastrointestinal decontamination
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.